Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00419263
Status:
COMPLETED
Last Update Posted:
2015-02-12
First Post:
2007-01-04
Brief Title:
Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza
Sponsor:
BioCryst Pharmaceuticals
Organization:
BioCryst Pharmaceuticals
Study Overview
Official Title:
A Phase II Multicenter Randomized Double-Mask Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study for patients with flu who also have a fever as well as other flu symptoms Patients must have had symptoms for less than 48 hours in order to participate Patients will have two out of three chances of getting an active study treatment and the other third will receive a placebo dummy drug Nobody will know who gets the active drug and who gets the inactive drug All patients will get supplies to treat symptoms of flu Patients will need to be seen 5 more times after they are enrolled in the study
Detailed Description:
Peramivir is a neuraminidase inhibitor that was previously shown to be effective in the treatment of human experimental influenza using an oral formulation Parenteral formulations of peramivir for intramuscular and intravenous injection entered clinical development at the time of this Phase 2 study A series of Phase 1 studies in human volunteers was completed that provided safety and pharmacokinetic results that supported the initiation of this Phase 2 multinational randomized double-mask study that compared the antiviral efficacy and safety of peramivir administered intramuscularly versus placebo in adults with uncomplicated acute influenza Because of the unique pharmacokinetic and pharmacodynamic properties of peramivir - a long terminal half life in plasma and an extended duration of binding to the neuraminidase enzyme - subjects were randomized in a 111 ratio to receive a single dose of one of three treatments peramivir 150 mg peramivir 300 mg and placebo Study drug was administered as one 2-mL intramuscular injection in each gluteal muscle total of 4 mL injected in divided doses This multinational study was originally to be conducted at approximately 80 sites in the US and Canada When enrollment during the North American influenza season of 2006-2007 did not achieve the target the study was extended to sites in Australia New Zealand South Africa and Hong Kong
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None